Background With current treatment options most patients with CNS TB develop severe
disability or die. Drug-resistant tuberculous meningitis is nearly uniformly fatal. Novel …

Background At a time when programs were struggling to design effective regimens for the
treatment of multidrug-resistant tuberculosis (MDR-TB), the marketing authorization of …

South African patients with rifampicin-resistant tuberculosis (TB) and resistance to
fluoroquinolones and/or injectable drugs (extensively drug-resistant (XDR) and preXDR-TB) …

CONTEXT Studies comparing initial therapy for multisystem inflammatory syndrome in
children (MIS-C) provided conflicting results. OBJECTIVE To compare outcomes in MIS-C …

Background Linezolid is increasingly important for multidrug-resistant tuberculosis (MDR-
TB) treatment. However, among children with MDR-TB, there are no linezolid …

We evaluated the in vitro activities of the antimicrobial drugs bedaquiline and delamanid
against the major pathogenic nontuberculous mycobacteria (NTM). Delamanid showed high …

Abstract Background In 2012, the Food and Drug Administration approved use of
bedaquiline fumarate as part of combination therapy for multidrug-resistant tuberculosis …

Antibiotics have been a key part of clinical treatments for more than 70 years. Long-term use
of antimicrobial treatments has led to the development of severe bacterial resistance, which …

Background The World Health Organization recommends standardised treatment durations
for patients with tuberculosis (TB). We identified and validated a host-RNA signature as a …

Objectives Patients with highly resistant tuberculosis have few treatment options.
Bedaquiline, pretomanid and linezolid regimen (BPaL) is a new regimen shown to have …